Last mentioned: Mar 6, 2026
Bioelectronic Medicine Forum
The forum convenes in NYC to discuss the future of neural interfaces.
2026 NYC Forum
Scheduled date for the Bioelectronic Medicine Forum in New York City.
Keynote Announcement
Jose Carmena announced as keynote for the 2026 Bioelectronic Medicine Forum in NYC.
Forum Announcement
Official announcement of the 2026 Bioelectronic Medicine Forum keynote and presenters.
Keynote Announcement
Iota Biosciences founder announced as the lead speaker for the NYC Forum.
Astellas Acquisition
Astellas Pharma acquires Iota Biosciences to bolster its 'Rx+' innovation strategy.
Astellas Acquisition
Astellas Pharma acquires Iota Biosciences in a deal valued at over $300 million.
Astellas Acquisition
Astellas Pharma acquires Iota Biosciences to bolster its Rx+ electronics division.
Iota Biosciences Founded
Jose Carmena and Michel Maharbiz spin out 'neural dust' technology from UC Berkeley.
Iota Biosciences Founded
Established as a spin-off from UC Berkeley to develop 'neural dust' technology.
The founder of Iota Biosciences will headline the 2026 Bioelectronic Medicine Forum in New York, marking a pivotal moment for the neurotechnology sector. The event will feature a global cohort of innovators, including European firms Coherence Neuro and Graphenicalab, alongside U.S. startup Spiro Medical.
The 2026 Bioelectronic Medicine Forum in New York City will feature a keynote from the founder of Iota Biosciences, a leader in miniaturized neural implants. The event highlights a growing international ecosystem of neurotech startups, including Coherence Neuro and Spiro Medical, focused on 'electroceuticals.'
Jose Carmena, co-founder of Iota Biosciences, has been named the keynote speaker for the 2026 Bioelectronic Medicine Forum in New York City. The event highlights the accelerating shift toward ultrasound-powered 'neural dust' and minimally invasive neuromodulation therapies.
The founder of Iota Biosciences has been named the keynote speaker for the 2026 Bioelectronic Medicine Forum in New York City. This announcement highlights the growing prominence of 'neural dust' technology and its potential to revolutionize chronic disease management through ultra-miniature bioelectronic implants.